This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaegi, A. Articles by Gent, M. Search for Related Content PubMed PubMed Citation Articles by Kaegi, A. Articles by Gent, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Dialysis Kidney Failure Hazardous Substances DB SULFINPYRAZONE

Circulation, Vol 52, 497-499, Copyright © 1975 by American Heart Association

ARTICLES

The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis

A Kaegi, GF Pineo, A Shimizu, H Trivedi, J Hirsh and M Gent

The effect of sulfinpyrazone on the incidence of thrombosis of arterio- venous shunts was investigated in a double-blind crossover study in 45 patients on chronic hemodialysis over a period of 12 months. The incidence of thrombosis was reduced from 0.64 thrombi per patient month when on placebo to 0.21 thrombi per patient month when on sulfinpryazone (P less than 0.001). The therapeutic effect was more striking in men than in women and became evident within a week of starting the drug. The side effects were minimal, requiring withdrawal from the study of only one patient. This crossover study strengthens the findings in the previous report that sulfinpyrazone is of value in the prevention of thrombosis.

This article has been cited by other articles:

				S. Hiremath, R. M. Holden, D. Fergusson, and D. L. Zimmerman Antiplatelet Medications in Hemodialysis Patients: A Systematic Review of Bleeding Rates Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1347 - 1355. [Abstract] [Full Text] [PDF]

				Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy BMJ, January 15, 1994; 308(6922): 159 - 168. [Abstract] [Full Text]

				Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]

				B. Aspey and M. Harrison Sex differences in the antithrombotic effectiveness of aspirin Vascular Medicine, September 1, 1990; 1(2): 113 - 119. [PDF]

				E. L. KINNEY, J. TRAUTMANN, J. A. GOLD, E. S. VESELL, and R. ZELIS Underrepresentation of Women in New Drug Trials: Ramifications and Remedies Ann Intern Med, October 1, 1981; 95(4): 495 - 499. [Abstract] [PDF]

				J. Hirsh Selection and Results of Antiplatelet Therapy in the Prevention of Stroke and Myocardial Infarction Arch Intern Med, February 23, 1981; 141(3): 311 - 315. [Abstract] [PDF]